JP2019501647A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501647A5
JP2019501647A5 JP2018528669A JP2018528669A JP2019501647A5 JP 2019501647 A5 JP2019501647 A5 JP 2019501647A5 JP 2018528669 A JP2018528669 A JP 2018528669A JP 2018528669 A JP2018528669 A JP 2018528669A JP 2019501647 A5 JP2019501647 A5 JP 2019501647A5
Authority
JP
Japan
Prior art keywords
chimeric receptor
domain
variant
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018528669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501647A (ja
JP7184645B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/064861 external-priority patent/WO2017096329A1/en
Publication of JP2019501647A publication Critical patent/JP2019501647A/ja
Publication of JP2019501647A5 publication Critical patent/JP2019501647A5/ja
Priority to JP2022187652A priority Critical patent/JP2023022161A/ja
Application granted granted Critical
Publication of JP7184645B2 publication Critical patent/JP7184645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018528669A 2015-12-03 2016-12-02 修飾キメラ受容体ならびに関連する組成物および方法 Active JP7184645B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022187652A JP2023022161A (ja) 2015-12-03 2022-11-24 修飾キメラ受容体ならびに関連する組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562262911P 2015-12-03 2015-12-03
US62/262,911 2015-12-03
US201662348130P 2016-06-09 2016-06-09
US62/348,130 2016-06-09
PCT/US2016/064861 WO2017096329A1 (en) 2015-12-03 2016-12-02 Modified chimeric receptors and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022187652A Division JP2023022161A (ja) 2015-12-03 2022-11-24 修飾キメラ受容体ならびに関連する組成物および方法

Publications (3)

Publication Number Publication Date
JP2019501647A JP2019501647A (ja) 2019-01-24
JP2019501647A5 true JP2019501647A5 (cg-RX-API-DMAC7.html) 2020-01-16
JP7184645B2 JP7184645B2 (ja) 2022-12-06

Family

ID=57851322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018528669A Active JP7184645B2 (ja) 2015-12-03 2016-12-02 修飾キメラ受容体ならびに関連する組成物および方法
JP2022187652A Pending JP2023022161A (ja) 2015-12-03 2022-11-24 修飾キメラ受容体ならびに関連する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022187652A Pending JP2023022161A (ja) 2015-12-03 2022-11-24 修飾キメラ受容体ならびに関連する組成物および方法

Country Status (10)

Country Link
US (1) US12139526B2 (cg-RX-API-DMAC7.html)
EP (2) EP3383892B1 (cg-RX-API-DMAC7.html)
JP (2) JP7184645B2 (cg-RX-API-DMAC7.html)
CN (2) CN116041538A (cg-RX-API-DMAC7.html)
AU (1) AU2016363025B2 (cg-RX-API-DMAC7.html)
CA (1) CA3007262A1 (cg-RX-API-DMAC7.html)
ES (1) ES2940607T3 (cg-RX-API-DMAC7.html)
MA (1) MA43380A (cg-RX-API-DMAC7.html)
MX (1) MX2018006789A (cg-RX-API-DMAC7.html)
WO (1) WO2017096329A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10228312B2 (en) 2012-02-23 2019-03-12 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
PT3132247T (pt) 2014-04-16 2021-11-03 Juno Therapeutics Gmbh Métodos, kits e aparelho para ampliar uma população de células
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
WO2016090190A1 (en) 2014-12-03 2016-06-09 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
JP7362249B2 (ja) * 2015-03-20 2023-10-17 チルドレンズ ナショナル メディカル センター ナイーブt細胞集団からのウイルスまたは他の抗原に特異的なt細胞の生成
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
WO2017068419A2 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
WO2018042385A2 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
EP3568469A4 (en) * 2017-02-21 2020-11-11 Eutilex Co., Ltd. COMPOSITIONS OF CAR-T CELLS DIRECTED AGAINST HLA-DR AND THEIR MANUFACTURING AND USE PROCEDURES
KR102624509B1 (ko) 2017-03-27 2024-01-12 싱가포르국립대학교 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
AU2018256436B2 (en) 2017-04-19 2024-12-05 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2018197949A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
CN118206655A (zh) * 2017-07-25 2024-06-18 得克萨斯大学体系董事会 增强的嵌合抗原受体及其用途
AU2018352245B2 (en) 2017-10-16 2025-07-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD22 immunotherapy
DK3704230T3 (da) 2017-11-01 2025-01-02 Juno Therapeutics Inc Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
BR112020008812A2 (pt) 2017-11-06 2020-10-27 Juno Therapeutics Inc combinação de terapia celular e um inibidor de gama secretase
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
US20210230289A1 (en) * 2018-06-12 2021-07-29 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
WO2020033927A2 (en) * 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
BR112021002487A2 (pt) 2018-08-10 2021-07-27 Eutilex Co., Ltd. receptor de antígeno quimérico que se liga a hla-dr e célula car-t
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US11464802B2 (en) 2019-04-09 2022-10-11 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
CN114364670B (zh) 2019-06-26 2025-06-13 纽力克斯治疗公司 用于Cbl-b抑制的取代苄基-三唑类化合物及其进一步用途
WO2021016606A1 (en) * 2019-07-24 2021-01-28 Eureka Therapeutics, Inc. Chimeric antigen receptor t cells and uses thereof
BR112022001702A2 (pt) * 2019-07-30 2022-06-21 Univ Health Network Moléculas mhc classe ii e métodos de uso das mesmas
EP4003965A1 (en) 2019-07-30 2022-06-01 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
AU2021219885B2 (en) * 2020-02-13 2025-07-24 Beijing Immunochina Pharmaceuticals Co., Ltd. Optimization of chimeric antigen receptor

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (cg-RX-API-DMAC7.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
AU4278296A (en) 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001043695A2 (en) 1999-10-27 2001-06-21 Cel-Sci Corporation Peptide constructs for treating autoimmune and related diseases
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
ES2353347T3 (es) 2000-08-21 2011-03-01 Apitope Technology (Bristol) Limited Péptido.
JP5312721B2 (ja) 2000-11-07 2013-10-09 シティ・オブ・ホープ Cd19特異的再指向免疫細胞
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20040138116A1 (en) 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20070264229A1 (en) 2004-09-13 2007-11-15 Strominger Jack L Peptides for Treatment of Autoimmune Disease
US20080118532A1 (en) 2006-06-01 2008-05-22 Atassi M Zouhair Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
DK2520643T3 (da) 2007-12-07 2020-01-20 Miltenyi Biotec Bv & Co Kg Prøvebehandlingssystemer og -fremgangsmåder
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
JP2012501180A (ja) 2008-08-26 2012-01-19 シティ・オブ・ホープ T細胞の抗腫瘍エフェクター機能増進のための方法および組成物
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
EP4049674A1 (en) 2009-11-03 2022-08-31 City of Hope Truncated epidermal growth factor receptor (egfrt) for transduced t cell selection
CA2806440A1 (en) 2010-08-06 2012-02-09 Ludwig-Maximilians-Universitaet Muenchen Identification of t cell target antigens
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012083069A2 (en) 2010-12-15 2012-06-21 The Board Of Trustees Of The Leland Stanford Junior University Measurement and monitoring of cell clonality
BR112013024395B1 (pt) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
EP3323833B1 (en) 2011-04-01 2019-12-04 Memorial Sloan-Kettering Cancer Center T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EP2776451B1 (en) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
JP2015511628A (ja) 2012-04-02 2015-04-20 ユニバーシティ オブ ブリストル 寛容化誘導組成物
CN104395462B (zh) 2012-05-03 2017-09-26 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
KR20150029714A (ko) * 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
SMT202100005T1 (it) 2012-08-20 2021-05-07 Hutchinson Fred Cancer Res Metodo e composizioni per immunoterapia cellulare
EP2903637B1 (en) 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
EP3114455B1 (en) 2014-03-04 2020-01-15 Merck Patent GmbH Robust antibody purification
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
PL3149031T3 (pl) 2014-05-29 2020-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptory limfocytów t przeciwko e7 wirusa brodawczaka ludzkiego 16
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
EP3215168B1 (en) 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof
WO2016090190A1 (en) 2014-12-03 2016-06-09 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
EP3271382B1 (en) 2015-03-16 2020-02-12 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
CN104910279B (zh) 2015-06-05 2019-02-22 重庆精准生物技术有限公司 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
EP3156067A1 (en) 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
ES2928167T3 (es) 2015-12-03 2022-11-15 Juno Therapeutics Inc Composiciones y métodos para reducir las respuestas inmunitarias contra receptores de antígenos quiméricos
CN108699557B (zh) 2015-12-04 2025-08-15 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules

Similar Documents

Publication Publication Date Title
JP2019501647A5 (cg-RX-API-DMAC7.html)
JP2019522465A5 (cg-RX-API-DMAC7.html)
JP2018525006A5 (cg-RX-API-DMAC7.html)
CN102906112B (zh) Trail r2-特异性多聚体支架
JP2017537919A5 (cg-RX-API-DMAC7.html)
JP2009529509A5 (cg-RX-API-DMAC7.html)
JP2020511949A5 (cg-RX-API-DMAC7.html)
JP2017527272A5 (cg-RX-API-DMAC7.html)
JP2019514361A5 (cg-RX-API-DMAC7.html)
JP2018512145A5 (cg-RX-API-DMAC7.html)
HRP20210498T1 (hr) De novo vezujuća domena koja sadrži polipeptide i njihova upotreba
RU2017134140A (ru) Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования
JP2011501951A5 (cg-RX-API-DMAC7.html)
JP2019527537A5 (cg-RX-API-DMAC7.html)
JP2017527310A5 (cg-RX-API-DMAC7.html)
JP2020505034A5 (cg-RX-API-DMAC7.html)
JP2018516092A5 (cg-RX-API-DMAC7.html)
HRP20220865T1 (hr) T stanični receptori
JP2019521643A5 (cg-RX-API-DMAC7.html)
JP2018515088A5 (cg-RX-API-DMAC7.html)
JP2019530441A5 (cg-RX-API-DMAC7.html)
RU2017144098A (ru) Гетеродимеризованный полипептид
JP2019522466A5 (cg-RX-API-DMAC7.html)
JP2018525033A5 (cg-RX-API-DMAC7.html)
FI4176894T3 (fi) Kimeerisiä tekijä viii -proteiineja ja niiden käyttötarkoituksia